GI
SRPT icon

GAMMA Investing’s Sarepta Therapeutics SRPT Stock Holding History

GAMMA Investing’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.5K Sell
2,699
-1,494
-36% -$28.3K ﹤0.01% 2312
2026
Q1 		$91.2K Buy
4,193
+127
+3% +$2.46K ﹤0.01% 1758
2025
Q4 		$87.5K Buy
4,066
+977
+32% +$20.6K ﹤0.01% 1679
2025
Q3 		$59.5K Buy
3,089
+2,288
+286% +$40.8K ﹤0.01% 1867
2025
Q2 		$13.7K Buy
801
+161
+25% +$6.87K ﹤0.01% 2655
2025
Q1 		$40.8K Sell
640
-214
-25% -$22.5K ﹤0.01% 1934
2024
Q4 		$104K Buy
854
+185
+28% +$22.7K 0.01% 1088
2024
Q3 		$83.6K Buy
669
+51
+8% +$7.05K 0.01% 1117
2024
Q2 		$97.6K Buy
618
+296
+92% +$38K 0.01% 794
2024
Q1 		$41.7K Buy
322
+87
+37% +$10.7K 0.01% 1160
2023
Q4 		$28K Buy
+235
New +$22.5K 0.01% 1267

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GAMMA Investing's SRPT Position: Q2 2026 in Review

GAMMA Investing reduced its Sarepta Therapeutics (SRPT) stake by 36% in Q2 2026, selling an estimated $28.3K and leaving 2,699 shares worth $48.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

GAMMA Investing first reported a position in SRPT in Q4 2023 and has held it in 11 quarters since. The position peaked at $104K in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • GAMMA Investing held 2,699 shares of Sarepta Therapeutics worth $48.5K as of Q2 2026.
  • GAMMA Investing sold 1,494 Sarepta Therapeutics shares in Q2 2026, an estimated $28.3K.
  • Sarepta Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2312 holding.
  • GAMMA Investing first reported a position in Sarepta Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Sarepta Therapeutics position peaked at $104K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.